Global Vaccine Market Poised for $94.9 Billion Valuation by 2029, Driven by mRNA Innovation and Emerging Markets
Table of Contents
The global vaccine market is experiencing sustained growth, fueled by lessons learned from the COVID-19 pandemic and advancements in vaccine technology. Market research firm Market & Market projects the industry will reach $94.9 billion by 2029, up from an estimated $78.5 billion in 2023.
Pandemic’s Lasting Impact and Technological Shifts
The COVID-19 pandemic underscored the critical role of vaccines in public health and spurred a paradigm shift in vaccine advancement. The world witnessed both qualitative and quantitative growth in the sector, prompting pharmaceutical and biotechnology companies to aggressively pursue global market share. This period of intense demand has begun to stabilize, but growth persists due to ongoing challenges like emerging viral variants, continued vaccination efforts for vulnerable populations, and the development of next-generation vaccines utilizing messenger ribonucleic acid (mRNA) technology.
Market Segmentation and Key Growth Drivers
Excluding COVID-19 vaccines, the broader vaccine market is projected to expand from $49 billion in 2023 to $80.3 billion in 2029, representing an average annual growth rate of 8.7%. Several vaccines are driving this expansion. Globally, cervical cancer (HPV), pneumococcal, and influenza vaccines remain major contributors.
A notable new market opportunity has emerged with the recent approval of GSK’s ‘Arexvy’ and Pfizer’s ‘Abrysvo’ by the U.S. Food and Drug Governance (FDA) in 2023, targeting respiratory syncytial virus (RSV). The RSV vaccine market is anticipated to experience a robust compound annual growth rate (CAGR) of 18.1% through 2029.
Shifting Market Leadership
The competitive landscape of the vaccine market has undergone a change as the onset of the pandemic.Prior to 2020, four companies – Pfizer, GSK, MSD (merck, USA), and Sanofi – controlled approximately 80% of the market share. However, this dominance has decreased to around 60% in 2024, as new players like Moderna and Novavax have entered the field, expanding the overall market size.
South Korea’s Rising Role in the Global Vaccine Landscape
The domestic vaccine market is also experiencing significant growth. According to Market & Market data, the South Korean market was valued at $870 million in 2023, representing 1.7% of the global total. This is expected to increase at an annual rate of 9.5%, reaching $1.49 billion by 2029.
GC Green Cross and SK Bioscience are the leading domestic vaccine manufacturers. LG Chem, Boryung Biopharma, and Ubiologics are also actively involved in vaccine production. South Korean vaccines are primarily exported to countries including Brazil, Sudan, Ethiopia, and Congo, with flu, cholera, and polio vaccines being the main export products.
Domestic Innovation and Pipeline Development
South Korean companies are heavily investing in vaccine research and development. As of December 2023, 36 domestic firms have a combined total of 108 vaccine research pipelines, focusing on areas such as COVID-19 (25 projects), influenza (12), HPV (10), and shingles (7). Recently approved domestic vaccines include SK Bioscience’s ‘Skycovidone’,eubiologics’ cholera vaccine ‘Uvicol-S’ and typhoid vaccine ‘Utif-C’,and GC Green Cross’ anthrax vaccine ‘Varitrax’.
Though, a critical gap remains in the development of vaccines for essential diseases like measles, rubella, and mumps (MMR).
The Need for Sustained Government Support
Experts emphasize the necessity of continued government support to ensure the domestic vaccine industry can compete effectively on a global scale. “Securing a stable supply chain for essential vaccines is challenging for companies to solve alone,” stated a senior industry official, adding that “profitability and public interest must be pursued together through government policy support and cooperation with international organizations.” Addressing structural challenges related to antigen procurement, clinical trial costs, and overall profitability is crucial for the long-term success of the South Korean vaccine industry.
